|
|
|
| The effect of Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis and its influence on inflammatory mediators |
| WANG Xuwei ZHANG Fubin LI Jun ZHANG Zunqi ZHANG Shiteng |
| Department of Emergency, PLA 105 Hospital, Anhui Province, Hefei 230031, China |
|
|
|
Abstract Objective To compare the efficacy of Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis and its influence on inflammatory mediators. Methods One hundred and eighteen cases of non biliary acute moderate and severe pancreatitis treated in PLA 105 Hospital from October 2015 to March 2017 were selected as research objects and divided into group A (61 cases) and group B (57 cases) according to random number table method. On the basis of routine treatment, group A and B were treated with Octreotide and somatostatin respectively for 7 days, and the recovery time of clinical indices, efficacy and complications of the two groups were compared. Results The recovery time on abdominal pain, fever, white blood cell count, serum amylase and the mean hospitalization time between the two groups had no significant differences (P ＞ 0.05). After treatment for 7 days, the differences on decreased acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) scores of the two groups were not statistically significant (P ＞ 0.05). The overall efficacy of the two groups had no significant difference (P ＞ 0.05); the decreased values of the two groups on tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, high-sensitivity C-reactive protein (hs-CRP) showed no statistically significant difference (P ＞ 0.05). The incidence of pancreatic pseudocyst, pulmonary infection, gastrointestinal bleeding, respiratory failure, flatulence in the two groups had no significant differences (P ＞ 0.05). Group A had a lower hypoglycemia rate than that of group B (P ＜ 0.05). Conclusion Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis has similar efficacy, both can significantly reduce inflammatory mediators, but hypoglycemia incidence is higher than that of somatostatin treatment.
|
|
|
|
|
|
[1] 李潇潇，葛庆岗，伊敏，等.2011～2015年北京大学第三医院成人住院患者营养药品应用调查[J].药物流行病学杂志，2017，26（2）：133-136.
[2] 邓红阳，戴蛟龙，张健，等.奥曲肽与生长抑素治疗急性胰腺炎的疗效比较[J].临床合理用药，2015，8（12）：53-54.
[3] 中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南（2014）[J].中华肝胆外科杂志，2015，21（1）：1-4.
[4] 李娜，孟江萍.血必净对重症肺炎患者的疗效分析[J].中国生化药物杂志，2014，34（5）：61-63.
[5] 陈彩霞，谢菲.生长抑素和生长激素联合应用对急性胰腺炎患者高敏C反应蛋白的影响[J].中国医师进修杂志，2012，35（29）：28-30.
[6] Fujino Y，Inoue Y，Onodera M，et al. Acute pancreatitis-induced thrombotic thrombocytopenic purpura with recurrent acutepancreatitis [J]. Clin J Gastroenterol，2016，9（2）：104-108.
[7] 陈亚奇，王彩芝，房修罗.奥曲肽联合生脉和硫酸镁治疗重症胰腺炎的临床疗效观察[J].临床医学，2012，32（3）：7-8.
[8] Jakkampudi A，Jangala R，Reddy BR，et al. NF-κB in acute pancreatitis：Mechanisms and therapeutic potential [J]. Pancreatology，2016，16（4）：477-488.
[9] 叶建华，俞松山.急性胰腺炎患者奥曲肽治疗对肠黏膜屏障功能的影响及疗效观察[J].放射免疫学杂志，2013，26（4）：529-530.
[10] Liu R，Wei N，Guo W，et al. Octreotide alleviates obesity by reducing intestinal glucose absorption and inhibiting low-grade inflammation [J]. Eur J Nutr，2013，52（3）：1067-1075.
[11] 常虹，陈佩婷，刘文正，等.胰管括约肌切开联合胰管支架对胆道微结石性急性复发性胰腺炎的疗效评价[J].中国微创外科杂志，2016，16（12）：1080-1084. |
|
|
|
